Comparison of serum CA-125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive ovarian adenocarcinoma.
Twenty-seven patients with frankly invasive nonmucinous invasive adenocarcinoma of the ovary were monitored using a serial CA-125 and lipid-associated sialic acid (LASA-P) levels prior to cytoreductive surgery, during chemotherapy, before second-look surgery or disease progression, and during subsequent follow-up. All levels were measured using previously described techniques. Serum LASA-P levels correlated well with CA-125 levels during all phases of treatment with no significant difference in predictive value of elevated or normal levels. LASA-P levels, thus, offer another, possibly less expensive, method of monitoring patients with invasive ovarian adenocarcinoma during therapy and in predicting the likelihood of a positive second-look laparotomy.
D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor / Q000097:blood*; D000939:Epitopes; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D019158:N-Acetylneuraminic Acid; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D012086:Reoperation; D012794:Sialic Acids / Q000097:blood*
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D000939:Epitopes; D008055:Lipids; D012794:Sialic Acids; C054080:lipid-associated sialic acid; D019158:N-Acetylneuraminic Acid